Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03843502 · ClinicalTrials.gov registry record · Phase 1

A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics

A Phase 1 study of Pharmacokinetics, sponsored by University of Florida.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT03843502 is a Phase 1 study of Pharmacokinetics that has completed, run by University of Florida. The registered enrollment target is 10 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03843502, a Phase 1 study of Pharmacokinetics, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Kava is a dietary supplement on the US market and is experiencing a resurgence of its use. Its pharmacokinetic information, however, is lacking which is important for its future effective usage as a dietary supplement or potentially as a botanical therapeutics. This phased trial, based on the recommendation from NIH, is to collect pharmacokinetic data of kava in healthy subjects.

Conditions Studied

Interventions

  • DRUG Kava Dietary Supplement

Study Locations (1)

Florida

  • UF CTSI Clinical Research Center - Gainesville

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-02-26
Est. Completion 2021-07-13
Phase Phase 1

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT03843502

The ClinicalTrials.gov registry entry for NCT03843502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (84% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which Kava Dietary Supplement is the first listed.

NCT03843502 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03843502 about?

NCT03843502 is a clinical study titled "A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics". Kava is a dietary supplement on the US market and is experiencing a resurgence of its use. Its pharmacokinetic information, however, is lacking which is important for its future effective usage as a dietary supplement or potentially as a botanical therapeutics. This phased trial, based on the recomm...

What is the current status of trial NCT03843502?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-02-26. Estimated completion is 2021-07-13.

What conditions does trial NCT03843502 study?

This clinical trial studies the following conditions: Pharmacokinetics.

What interventions are being tested in trial NCT03843502?

The interventions under investigation include: Kava Dietary Supplement (DRUG).

Who is sponsoring clinical trial NCT03843502?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03843502 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pharmacokinetics

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.